Patents by Inventor Andrea Aloia

Andrea Aloia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BENZO[H]QUINAZOLIN-4-AMINE AND THIENO[3,2-H]QUINAZOLIN-4-AMINE DERIVATIVES FOR THE TREATMENT OF CANCER
    Publication number: 20230365509
    Abstract: The invention provides compounds of formula (IA) and compounds of formula (IB) and pharmaceutically acceptable salts thereof; wherein A is selected from group (A1) and group (A2): wherein #1 is attached to the carbon atom forming the oxime moiety and wherein group (A1) is optionally substituted by one or two R10 and group (A2) is optionally substituted by one R10, and wherein R1, X, R2 and R10 are as defined in the claims, as well as methods of using the compounds to treat neoplastic diseases, in particular cancer.
    Type: Application
    Filed: October 7, 2021
    Publication date: November 16, 2023
    Inventors: Sven Weiler, Bérangère Gaucher, Florian Richalet, Stefan Reinelt, Thomas Radimerski, Andrea Aloia
  • Chimeric antigen receptor specific for SSEA4 antigen
    Patent number: 10273295
    Abstract: The present invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain specific for SSEA4, a population of engineered cells expressing said CARs, and a pharmaceutical composition comprising said genetically modified cells expressing said CARs. The pharmaceutical composition may be for use of the treatment of cancer in a subject suffering from cancer, wherein at least a subpopulation of the cancerous cells of said cancer expresses SSEA4.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: April 30, 2019
    Assignee: Miltenyi Biotec GmbH
    Inventors: Andreas Bosio, Olaf Hardt, Andrea Aloia
  • Chimeric Antigen Receptor Specific for SSEA4 Antigen
    Publication number: 20170283489
    Abstract: The present invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain specific for SSEA4, a population of engineered cells expressing said CARs, and a pharmaceutical composition comprising said genetically modified cells expressing said CARs. The pharmaceutical composition may be for use of the treatment of cancer in a subject suffering from cancer, wherein at least a subpopulation of the cancerous cells of said cancer expresses SSEA4.
    Type: Application
    Filed: August 12, 2015
    Publication date: October 5, 2017
    Inventors: Andreas Bosio, Olaf Hardt, Andrea Aloia
  • SSEA4 AND ST3GAL2 AS CHEMOTHERAPEUTIC DRUG RESPONSE BIOMARKERS
    Publication number: 20150316556
    Abstract: The present invention provides the use of the biomarkers SSEA4 and/or ST3GAL2 for assessing the outcome for chemotherapeutic treatment of a cancer in an individual and methods thereof.
    Type: Application
    Filed: March 31, 2015
    Publication date: November 5, 2015
    Inventors: Olaf Hardt, Andreas Bosio, Andrea Aloia, Jean-Gabriel Judde, Evgeniya Petrova, Stefano Cairo, Olivier Deas